Skip to content
DataLookout
Menu

NCT04094298

Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease

StatusTerminated
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 10 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial terminated Sponsor's reason: The primary reasons for early study termination are administrative and funding issues and inability to obtain the investigational product; this lead to insufficient participant enrollment. Show 8 more changesShow less
    • Study completion date changed from estimate of Jan 31, 2025 to Oct 9, 2025
    • Results posted: Nov 4, 2026
    • Start date: Jul 15, 2019 to Aug 27, 2020
    • Eligibility criteria expanded, about 12 words
    • Final enrollment: 40 participants (planned 65)
    • Secondary endpoints revised (4)
    • Primary endpoint revised
    • Publications: details revised at 5 of 5 entries
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Dec 1, 2024 to Oct 10, 2024
    • Study completion date: Dec 1, 2024 to Jan 31, 2025
    • Site details revised
    v12
  3. Notable Primary completion date: Dec 1, 2023 to Dec 1, 2024v10
  4. Minor Primary completion date: Sep 1, 2023 to Dec 1, 2023
    • Study completion date: Sep 1, 2024 to Dec 1, 2024
    v9
  5. Minor Site contact updatedv8
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Primary completion date: Sep 1, 2021 to Sep 1, 2023
    • Study completion date: Sep 1, 2022 to Sep 1, 2024
    • Collaborators shortened, about 3 words
    v7
  2. Notable Trial status: Suspended to Recruiting
    • Site details revised
    v5
  3. Minor Study site revised
    • Collaborator revised
    v4
  4. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Institutional roadblocks.
    • Site details revised
    v3
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of Adverse Events
Timeframe: 24 weeks

Secondary (4)

Change in Shoulder Pain as Assessed by VAS
Change in Shoulder Function as Assessed by SANE
Change in Shoulder Function as Assessed by VR-12
Change in Shoulder Function as Assessed by ASES

Arms and interventions

Treatment GroupExperimental

Patients receiving the 32-unit injection of FX006.

Drugs: FX006 Injection

Sites

1 site in 1 country

  • Northwell Health Orthopedic Institute at Great NeckGreat Neck, New York, United States